Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
6.78
+0.21 (3.20%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Valneva SE Employees
Valneva SE had 713 employees as of December 31, 2024. The number of employees increased by 37 or 5.47% compared to the previous year.
Employees
713
Change (1Y)
37
Growth (1Y)
5.47%
Revenue / Employee
$246,234
Profits / Employee
-$17,783
Market Cap
577.05M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
VALN News
- 2 days ago - Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers - GlobeNewsWire
- 4 days ago - Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 6 days ago - Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine - Benzinga
- 6 days ago - Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country - GlobeNewsWire
- 11 days ago - Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2 - GlobeNewsWire
- 13 days ago - VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm - PRNewsWire
- 17 days ago - Valneva SE Shareholding Declaration - March 2025 - GlobeNewsWire
- 19 days ago - Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above - GlobeNewsWire